Intra-arterial chemotherapy of advanced pancreatic cancer: A single center experience

Hepato-Gastroenterology

Volumn 54, Issue 80, 2007, Pages 2373-2377

  Milandri, Carlo ^a   Calzolari, Filippo ^b   Passardi, Alessandro ^a   Tison, Chiara ^a   Giampalma, Emanuela ^c   Cecconetto, Lorenzo ^a   Golfieri, Rita ^c  

^a DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^b MORGAGNI PIERANTONI HOSPITAL   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

FLEC regimen; Intra arterial chemotherapy; Liver metastases; Pancreatic cancer

Indexed keywords

CARBOPLATIN; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; GASTRITIS; HUMAN; LEUKOPENIA; LIVER METASTASIS; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; DISEASE PROGRESSION; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRA-ARTERIAL; LEUCOVORIN; LIVER NEOPLASMS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 37749038699     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Greenlee RT, Hill-Harmon MB, Thun TM: Cancer statistics 2001. CA Cancer J Clin 2001; 51:15-36.
2. Brennan MF, Kinsella TJ, Casper ES: Cancer of the pancreas: In: DeVita VT Jr, Hellman S, Rosenberg SA (Eds.). Cancer: Principles and Practice of Oncology. 4th Edition. Philadelphia, PA: Lippincott Williams & Wilkins, 1993; pp. 849-882.
3. Schnall SF, Macdonald JS: Chemotherapy of adenocarcinoma of the pancreas. Semin Oncol 1996; 23:220-228.
4. Stephens CD: Gemcitabine: a new approach to treating pancreatic cancer. Oncol Nurs Forum 1998; 25:87-93.
5. Evans DB, Abbruzzese JL, Tyvin AR: Cancer of the pancreas. In: DeVita VT Jr, Hellman S, Rosenberg SA (Eds.). Cancer: Principles and Practice of Oncology. 4th Edition. Philadelphia, PA: Lippincott Williams & Wilkins. 1997; pp. 1054-1087.
6. Casper ES: Pancreatic cancer: how can we progress? Eur J Cancer 1993; 29A:171-172.
7. Cullinan S, Moertel CG, Wieand HS, et al: A phase III trial on the therapy of advanced pancreatic carcinoma: evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin. Cancer 1990; 65:2207-2212.
8. Burris HA 3rd, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15:2403-2413.
9. Storniolo AM, Enas NH, Brown CA, Voi M, Rothenberg ML, Schilsky R: An investigational new drug treatment program for patients with gemcitabine. Cancer 1999; 85:1261-1268.
10. Ryan DP, Kulke MH, Fuchs CS, et al: A phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma. Cancer 2002; 94:97-103.
11. Philip PA, Zalupski MM, Vaitkevicius VK, et al: Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma. Cancer 2001; 92:569-577.
12. Louvet C, Andre T, Hammel P, et al: Phase II trial of bimonthly leucovorin, 5-fluorouracil and gemcitabine for advanced pancreatic adenocarcinoma (FOLFUGEM). Ann Oncol 2001; 12:675-679.
13. Louvet C, Andre T, Lledo G, et al: Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study. J Clin Oncol 2002; 20:1512-1518.
14. Rocha Lima CM, Savarese D, et al: Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer. J Clin Oncol 2002; 20:1182-1191.
15. Colucci G, Giuliani F, Gebbia V, et al: Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale. Cancer 2002; 94:902-910.
16. Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, Benson AB 3rd: Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 2002; 20:3270-3275.
17. Stehlin JS, Giovanella BC, Natelson EA, et al: A study of 9-nitrocamptothecin (RFS 2000) in patients with advanced pancreatic cancer. Int J Oncol 1999; 14:821-831.
18. Sharma S, Kemeny N, Schwartz GK, et al: Phase I study of topoisomerase I inhibitor exatecan mesylate (DX-8951f) given as weekly 24-hour infusions three or every four weeks. Clin Cancer Res 2001; 7:3963-3970.
19. Collins JM: Pharmacologic rationale for regional drug delivery. J Clin Oncol 1984; 2:498-504.
20. Link KH, Kindler D, Hummel M, Buchler M: Dose response treatment studies with two pancreatic carcinoma cell lines in vitro. Digestion 1992; 52:102A.
21. Link KH, Gansauge F, Pillasch J, et al: Regional treatment of advanced non resectable and of resected pancreatic cancer via celiac axis infusion. Dig Surg 1995; 11:414-419.
22. Aigner KR, Muller H, Basserman R: Intra-arterial chemotherapy with MMC, CDDP, and 5-FU for non resectable pancreatic cancer: a phase II study. Reg Cancer Treat 1990; 3:1-6.
23. Muchmore JH, Preslan JE, George WJ: Regional chemotherapy for inoperable pancreatic cancer. Cancer 1996; 78 (3 Suppl):S664-673.
24. Ohigashi H, Hishikawa O, Nakamori S, et al: Evaluation of intra-arterial infusion chemotherapy and radical pancreatectomy in patients with locally advanced pancreatic cancer. Gan To Kagaku Ryoho 1993; 20:1672-1675.
25. Tanaka H, Taniguchi H, Koyoma H, et al: A case of complete response by intermittent intra-arterial injection of 5-flurouracil and carboplatin for liver metastases due to pancreatic cancer. Gan To Kagaku Ryoho 1993; 20:1669-1671.
26. Cantore M, Pederzoli P, Cornalba G, et al: Intra-arterial chemotherapy for unresectable pancreatic cancer. Ann Oncol 2000; 11:569-573.
27. Goldstein LJ, Galski H, Fojo A, et al: Expression of the multidrug resistance gene product P-glycoprotein in human cancer. J Natl Cancer Inst 1989; 81:116-124.
28. Ishida H, Makino T, Kobayashi M, Tsuneoka K: Laparoscopic measurement of pancreatic blood flow. Endoscopy 1983; 15:107-110.
29. Louvet C, Labianca R, Hammel P, et al: GemOx (gemcitabine + oxaliplatin) versus Gem (gemcitabine) in non resectable pancreatic adenocarcinoma: final results of the GERCOR/GISCAD Intergroup Phase III. Proc Am Soc Clin Oncol 2004; 22:4008. (Abstract)
30. Reni M, Cordio S, Milandri C, et al: Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomized controlled multicentre phase III trial. Lancet Oncol, 2005; 6:369-376.
31. Xiong HQ, Rosenberg A, LoBuglio A, et al: Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic: a multicentric phase II trial. J Clin Oncol 2004; 22:2610-2616.
32. Moore MJ, Goldstein D, Hamm J, et al: Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG]. Proc Am Soc Clin Oncol 2005; 23:1. (Abstract)
33. Cantore M, Fiorentini G, Luppi M, et al: Randomized trial of gemcitabine versus FLEC regimen given intra-arterially for patients with unresectable pancreatic cancer. J Exp Clin Cancer Res 2003; 22(4 Suppl):51-57.
34. Barletta E, Fiore F, Daniele B, et al: Second-line intra-arterial chemotherapy in advanced pancreatic adenocarcinoma. Front Biosci 2006; 1:782-787.